The Claim
GLP-1 receptor agonists reduce the risk of major adverse cardiovascular events (MACE) by 17% in patients with type 2 diabetes and established atherosclerotic cardiovascular disease, based on pooled data from seven randomized controlled trials involving 38,642 patients, with an absolute risk reduction of 2.12% over three years and a number needed to treat of 47 to prevent one MACE event.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
In patients with type 2 diabetes and established atherosclerotic cardiovascular disease, GLP-1 receptor agonists lower the occurrence of major adverse cardiovascular events by 17% compared to no such treatment, with an absolute reduction of 2.12% over three years.
See the scientific wording
GLP-1 receptor agonists reduce the risk of major adverse cardiovascular events (MACE) by 17% in type 2 diabetes patients with established atherosclerotic cardiovascular disease (ASCVD), based on pooled data from seven randomized controlled trials involving 38,642 patients, with an absolute risk reduction of 2.12% over three years and a number needed to treat of 47 to prevent one MACE event.
GLP-1 receptor agonists slow the buildup of fatty plaques in arteries and make existing plaques less likely to rupture, which prevents heart attacks and strokes.
What the research says
1 studyFor people with type 2 diabetes and existing heart disease, taking GLP-1 drugs lowers the chance of heart attacks or strokes by about 1 in 47 over three years — and this study proves it by looking at thousands of patients.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.